John Davies is listed as an executive officer and director on 2 SEC Form D filings by 1 issuer between Aug 2022 and Apr 2024: Gemina Laboratories Ltd. (Burnaby, British Columbia, Canada (as filed: A1) — biotechnology — 2022–2024; $370K reported sold to 3 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Martin Cronin (2 shared filings), Bola Grace (1 shared filing), Brian Firth (1 shared filing), Davis Rokoss (1 shared filing), James Tansey (1 shared filing) and 5 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around John. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for John Davies and found 10 differences: Form D filed 28 days after the first sale; John Davies's role changed at Gemina Laboratories Ltd.: executive officer, director → director; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.